Constellation pharmacology: a new paradigm for drug discovery
about
Metabolic model for diversity-generating biosynthesisClassifying neuronal subclasses of the cerebellum through constellation pharmacology.(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.Advances in venomics.Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.A bimodal activation mechanism underlies scorpion toxin-induced pain.
P2860
Constellation pharmacology: a new paradigm for drug discovery
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Constellation pharmacology: a new paradigm for drug discovery
@ast
Constellation pharmacology: a new paradigm for drug discovery
@en
Constellation pharmacology: a new paradigm for drug discovery
@nl
type
label
Constellation pharmacology: a new paradigm for drug discovery
@ast
Constellation pharmacology: a new paradigm for drug discovery
@en
Constellation pharmacology: a new paradigm for drug discovery
@nl
prefLabel
Constellation pharmacology: a new paradigm for drug discovery
@ast
Constellation pharmacology: a new paradigm for drug discovery
@en
Constellation pharmacology: a new paradigm for drug discovery
@nl
P2093
P2860
P1476
Constellation pharmacology: a new paradigm for drug discovery
@en
P2093
Baldomero M. Olivera
Eric W. Schmidt
Russell W. Teichert
P2860
P304
P356
10.1146/ANNUREV-PHARMTOX-010814-124551
P407
P577
2015-01-01T00:00:00Z